AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection

Garczyk S, Von Stillfried S, Antonopoulos W, Hartmann A, Schrauder MG, Fasching P, Anzeneder T, Tannapfel A, Ergoenenc Y, Knuechel R, Rose M, Dahl E (2015)

Publication Type: Journal article

Publication year: 2015

Journal

PLoS ONE Public Library of Science

Book Volume: 10

Pages Range: e0122106

Journal Issue: 4

DOI: 10.1371/journal.pone.0122106

Abstract

Blood-based early detection of breast cancer has recently gained novel momentum, as liquid biopsy diagnostics is a fast emerging field. In this study, we aimed to identify secreted proteins which are up-regulated both in tumour tissue and serum samples of breast cancer patients compared to normal tissue and sera. Based on two independent tissue cohorts (n = 75 and n = 229) and one serum cohort (n = 80) of human breast cancer and healthy serum samples, we characterised AGR3 as a novel potential biomarker both for breast cancer prognosis and early breast cancer detection from blood. AGR3 expression in breast tumours is significantly associated with oestrogen receptor ? (P<0.001) and lower tumour grade (P<0.01). Interestingly, AGR3 protein expression correlates with unfavourable outcome in low (G1) and intermediate (G2) grade breast tumours (multivariate hazard ratio: 2.186, 95% CI: 1.008-4.740, P<0.05) indicating an independent prognostic impact. In sera analysed by ELISA technique, AGR3 protein concentration was significantly (P<0.001) elevated in samples from breast cancer patients (n = 40, mainly low stage tumours) compared to healthy controls (n = 40). To develop a suitable biomarker panel for early breast cancer detection, we measured AGR2 protein in human serum samples in parallel. The combined AGR3/AGR2 biomarker panel achieved a sensitivity of 64.5% and a specificity of 89.5% as shown by receiver operating characteristic (ROC) curve statistics. Thus our data clearly show the potential usability of AGR3 and AGR2 as biomarkers for blood-based early detection of human breast cancer.

Authors with CRIS profile

Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen DE Germany (DE) Patients' Tumor Bank of Hope PATH Biobank DE Germany (DE) Ruhr-Universität Bochum (RUB) DE Germany (DE) St. Elisabeth Gruppe GmbH - Katholische Kliniken Rhein-Ruhr DE Germany (DE)

How to cite

APA:

Garczyk, S., Von Stillfried, S., Antonopoulos, W., Hartmann, A., Schrauder, M.G., Fasching, P.,... Dahl, E. (2015). AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection. PLoS ONE, 10(4), e0122106. https://doi.org/10.1371/journal.pone.0122106

MLA:

Garczyk, Stefan, et al. "AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection." PLoS ONE 10.4 (2015): e0122106.

BibTeX: Download